CD8A and neoplasm: In patients responding to PD-1 inhibitors, neoantigen immunotherapy can induce the expansion of PD-1+ CD8+ T cells, resulting in a temporary increase in PD-1+ CD8+ T cell circulation and the infiltration of effector T cells at the tumor site.